AAAAI 2020, News
High doses of inhaled corticosteroids were associated with lower levels of eosinophils, which may interfere with the recommendation of some monoclonal antibodies in asthma treatment.
ACR 2019, News
Researchers evaluated the efficacy and safety of guselkumab in patients with active psoriatic arthritis who were biologic-naive or treated with prior tumor necrosis factor inhibitors.
ACAAI 2019, News
Mepolizumab reduced the number of exacerbations in patients with severe asthma, but exacerbations per month remained relatively stable throughout the year without a clear seasonal influence.
This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, conducted by experts in the field. Check back regularly for more news from AAO 2019. SAN FRANCISCO – For patients with progressive Acanthamoeba…
Age- and sex-stratified comorbidity and concomitant medication use has been found among individuals with MS who have newly initiated disease-modifying drugs.
Patients with both asthma and allergies had a significant increase in the number of prescriptions dispensed for controller medications.
Oral contraceptive use in women of reproductive age may increase the risk for lifetime asthma.
AAN 2016 General News
Treatment with oral dexamethasone for 4 days significantly improved pain levels in the majority of outpatients with status migrainosus, a retrospective chart review presented at the 68th AAN Annual Meeting has found.
ACR/ARHP Annual Meeting 2015
Ustekinumab (UST) benefits patients with psoriatic arthritis (PsA) with spondylitis and peripheral joint involvement, according to an post-hoc analysis of results from the PSUMMIT 1 & 2 phase 3 double-blind, placebo-controlled clinical trials, reported at the 2015 ACR/ARHP Annual Meeting.
Treatment with single-agent carfilzomib achieved durable responses in patients with relapsed/refractory multiple myeloma whose disease had relapsed after they received all available therapies (including bortezomib and immunomodulatory agents), suggesting that this agent has the potential to offer substantial clinical benefit. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.